Managing enlarged prostate in primary care
Summary Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical...
Saved in:
| Published in | International journal of clinical practice (Esher) Vol. 60; no. 12; pp. 1609 - 1615 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.12.2006
Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical management of this condition. Commensurate with the long‐term preventive role of primary care, efforts can and should be made to treat the underlying condition of enlarged prostate as well as to manage the symptoms short‐term. This review outlines evaluation of men presenting with lower urinary tract symptoms, examines the challenges for medical treatment and suggests how treatment choice can address these challenges. |
|---|---|
| AbstractList | Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical management of this condition. Commensurate with the long-term preventive role of primary care, efforts can and should be made to treat the underlying condition of enlarged prostate as well as to manage the symptoms short-term. This review outlines evaluation of men presenting with lower urinary tract symptoms, examines the challenges for medical treatment and suggests how treatment choice can address these challenges. Summary Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical management of this condition. Commensurate with the long‐term preventive role of primary care, efforts can and should be made to treat the underlying condition of enlarged prostate as well as to manage the symptoms short‐term. This review outlines evaluation of men presenting with lower urinary tract symptoms, examines the challenges for medical treatment and suggests how treatment choice can address these challenges. |
| Author | NASLUND, M. J. MINER, M. M. COSTA, F. J. |
| Author_xml | – sequence: 1 givenname: M. J. surname: NASLUND fullname: NASLUND, M. J. organization: Division of Urology, University of Maryland School of Medicine, Baltimore, MD, USA – sequence: 2 givenname: F. J. surname: COSTA fullname: COSTA, F. J. organization: Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA – sequence: 3 givenname: M. M. surname: MINER fullname: MINER, M. M. organization: Department of Family Medicine, Brown University School of Medicine, Providence, Rhode Island, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18880077$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17109668$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkFtPwyAcxYmZcfPyFUxf9MGklT9QoC8mOu_TabzER8IoLJ1dp2WL89tLXTNf5YWT8DuHk7ONOtWssghFgBMI53iSgGAkBsIgIRjzBANkLFluoN76oRM05TJOMYUu2vZ-gjFJU4m3UBcE4Ixz2UNH97rS46IaR7YqdT22efRRz_xcz21UVEEXU11_R0bXdhdtOl16u9feO-j18uKlfx3fPVzd9E_vYsMkZzHBHDjPHDeEUpYZC8ySkaFEYnDYsoy5nLjcpVRkZCRcLjKXSh28OYxSRukOOlzlhiKfC-vnalp4Y8tSV3a28IpL4IxzCKBcgSY09rV1qq2rAKtmJzVRzRyqmUM1O6nfndQyWPfbPxajqc3_jO0wAThoAe2NLl2tK1P4P05KibEQgTtZcV9Fab__XUDd3PYfGxkC4lVA4ed2uQ7Q9bvigopUvQ2v1LD_NHg-G5yrc_oDuxmSYQ |
| CitedBy_id | crossref_primary_10_3889_oamjms_2022_10369 crossref_primary_10_1111_ijcp_12305 crossref_primary_10_1111_j_1742_1241_2007_01491_x crossref_primary_10_1007_s11934_009_0042_7 crossref_primary_10_1111_j_1742_1241_2009_02304_x crossref_primary_10_1007_s11918_009_0011_0 crossref_primary_10_1111_j_1745_7599_2007_00243_x |
| Cites_doi | 10.1016/S0090-4295(98)00654-2 10.1016/j.urology.2004.08.049 10.1016/S0022-5347(05)67962-1 10.1016/j.urology.2004.01.001 10.1016/S0022-5347(01)61621-5 10.1056/NEJMoa030656 10.1016/S0960-0760(99)00030-8 10.1097/00005392-199904020-00076 10.1016/S0090-4295(01)01201-8 10.1016/S0022-5347(05)64471-0 10.1016/S0090-4295(98)00655-4 10.1016/S0090-4295(98)00126-5 10.1016/S0140-6736(00)02389-8 10.1016/S0022-5347(05)67984-0 10.1056/NEJM199610033351401 10.1016/j.eururo.2006.02.018 10.1016/S0090-4295(02)01905-2 10.1016/S0022-5347(01)62386-3 10.1016/S0022-5347(05)65010-0 10.1056/NEJM199811053391902 10.1097/01.ju.0000155709.37840.fe 10.1016/S0090-4295(01)01448-0 10.1210/jc.2003-030330 10.1016/S0090-4295(01)01298-5 10.1001/jama.279.20.1615 10.1016/S0022-5347(17)49698-4 10.1056/NEJM199803123381107 10.1097/01.ju.0000139539.94828.29 10.1016/S0022-5347(01)66461-9 10.1016/S0022-5347(01)63011-8 10.1159/000052475 10.1056/NEJM199802263380901 10.1007/s00345-002-0301-4 10.1097/01.ju.0000078083.38675.79 10.1016/S0022-5347(17)36966-5 10.1016/S0022-5347(01)64508-7 10.1016/0090-4295(91)80191-9 10.1159/000020181 10.1111/j.1464-410X.2006.06110.x 10.1056/NEJM199501123320202 10.1016/j.urology.2003.09.063 10.1056/NEJM199511163332001 10.1016/S0022-5347(01)65267-4 10.1056/NEJM199309303291401 10.4065/80.10.1356 10.1016/S0090-4295(99)80008-9 10.1016/S0090-4295(00)01021-9 10.1016/S0090-4295(00)00743-3 10.1016/j.eururo.2003.09.012 10.1016/S0302-2838(03)00367-1 |
| ContentType | Journal Article |
| Copyright | 2007 INIST-CNRS |
| Copyright_xml | – notice: 2007 INIST-CNRS |
| DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1111/j.1742-1241.2006.01194.x |
| DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-1241 |
| EndPage | 1615 |
| ExternalDocumentID | 10_1111_j_1742_1241_2006_01194_x 17109668 18880077 IJCP1194 ark_67375_WNG_NCRKSBKD_D |
| Genre | reviewArticle Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 24P 29J 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAJEY AAONW AAWTL AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACGFO ACGFS ACMXC ACPOU ACPRK ACSCC ACXQS ADBBV ADEOM ADIYS ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFFNX AFGKR AFPWT AFRAH AFZJQ AHMBA AIACR AIAGR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA GROUPED_DOAJ H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PGMZT PQQKQ Q.N Q11 QB0 R.K RHX ROL RPM RX1 SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI X7M XG1 ZGI ZXP ZZTAW ~IA ~WT AAPBV AAUGY AAVGM ABHUG ACXME ADAWD AFVGU AGJLS AJAOE AKALU IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c4864-2061669f6c23349ce14e2bc32801f0e494fd2fdf53792b7fd79f58a486d1b5433 |
| IEDL.DBID | DR2 |
| ISSN | 1368-5031 |
| IngestDate | Fri Aug 16 04:07:42 EDT 2024 Fri Aug 23 02:43:47 EDT 2024 Sat Sep 28 07:51:25 EDT 2024 Sun Oct 29 17:08:47 EDT 2023 Sat Aug 24 01:13:49 EDT 2024 Wed Oct 30 09:50:47 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | Urinary system disease Prostate disease Primary health care enlarged prostate Urinary tract disease Medicine Voiding dysfunction Treatment Benign prostatic hyperplasia primary care Benign neoplasm Diagnosis Male genital diseases Lower urinary tract symptoms |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4864-2061669f6c23349ce14e2bc32801f0e494fd2fdf53792b7fd79f58a486d1b5433 |
| Notes | ark:/67375/WNG-NCRKSBKD-D istex:32608B51E3A686DC756ECBC5629F30DDDB8CB3A5 ArticleID:IJCP1194 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://doi.org/10.1111/j.1742-1241.2006.01194.x |
| PMID | 17109668 |
| PQID | 68164661 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_68164661 crossref_primary_10_1111_j_1742_1241_2006_01194_x pubmed_primary_17109668 pascalfrancis_primary_18880077 wiley_primary_10_1111_j_1742_1241_2006_01194_x_IJCP1194 istex_primary_ark_67375_WNG_NCRKSBKD_D |
| PublicationCentury | 2000 |
| PublicationDate | December 2006 |
| PublicationDateYYYYMMDD | 2006-12-01 |
| PublicationDate_xml | – month: 12 year: 2006 text: December 2006 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | International journal of clinical practice (Esher) |
| PublicationTitleAlternate | Int J Clin Pract |
| PublicationYear | 2006 |
| Publisher | Blackwell Publishing Ltd Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
| References | Scientific Committee of the First International Consultation on Incontinence. Assessment and treatment of urinary incontinence. Lancet 2000; 355: 2153-8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57. Andriole G, Bruchovsky N, Chung LWK et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004; 172: 1399-403. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734-41. McConnell JD, Roehrborn CG, Bautista OM et al. for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-47. Sacks FM, Pfeffer MA, Moye LA et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9. Jacobsen SJ, Girman CJ, Guess HA et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600. Beckman TJ, Mynderse LA. Evaluation and management of benign prostatic hyperplasia. Mayo Clin Proc 2005; 80: 1356-62. Clark RV, Hermann DJ, Cunningham GR et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701-6. Rhodes T, Girman CJ, Jacobsen SJ et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 70 years old. J Urol 1999; 161: 1174-9. Boyle P, Roehrborn CG, Harkaway R et al. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004; 45: 620-7. Barry MJ, Fowler FJ, Bin L et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157: 10-4. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61. Roehrborn CG, Boyle P, Nickel JC et al. on behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41. Kuritzky L. A primary care physician's perspective on benign prostatic hyperplasia. Rev Urol 2003; 5 (Suppl. 5): S42-S48. Garraway WM, Russell EB, Lee RJ et al. Impact of previously unrecognized benign prostatic hyperplasia on daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 318-21. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39: 390-9. Ielhé C, Radvanyi F, Gil Diez de Medina S et al. Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189-95. Roehrborn CG, for the Alfus Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58: 953-9. Clark RV, Hermann DJ, Hoda G et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel 5 alpha reductase inhibitor. J Urol 1999; 161 (Suppl. 4): 268. Lepor H, for the Terazosin Research Group. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406-13. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-59. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57. Flanigan RC, Reda DJ, Wasson JH et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-6. Djavan B, Fong YK, Harik M et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004; 64: 1144-8. Wright EJ, Fang J, Metter EJ et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167: 2484-8. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-46. Kaplan SA. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning. Urology 2004; 63: 428-34. Barkin J, Guimarães M, Jacobi G et al. for the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5α-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461-6. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001; 58: 203-9. Roehrborn CG, McConnell J, Bonilla J et al. for the PROSCAR Long-Term Efficacy and Safety Study. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000; 163: 13-20. McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J, Roehrborn CG. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 2001; 57: 459-65. Sarma AV, Jacobsen SJ, Girman CJ et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002; 168: 1446-52. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58 (Suppl. 6A): 5-16. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor or prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53: 581-9. Roehrborn CG. Acute relief or future prevention: is urology ready for preventive health care? Urology 2000; 56 (Suppl. 5A): 12-9. Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004; 63: 709-15. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998; 51: 892-900. Wasson JH, Reda DJ, Bruskewitz RC et al. for the Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86. Roberts RO, Jacobsen SJ, Jacobson DJ et al. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000; 163: 107-13. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. Roehrborn CG, McConnell JD, Lieber M et al. for the PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473-80. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia. N Engl J Med 1995; 333: 1301-7. McConnell JD, Bruskewitz R, Walsh P et al. for The Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatitic hyperplasia. N Engl J Med 1998; 338: 557-63. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000; 37: 367-80. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. Urology 1991; 38 (Suppl.): 4-8. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human prostatic hyperplasia with age. J Urol 1984; 132: 474-9. Downs J, Clearfield M, Weis S et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-22. 1997; 157 1997; 158 1998; 160 2004; 63 2004; 64 1991; 38 2005; 173 2006; 97 1993; 329 2000; 355 1993; 43 2004; 45 2004; 89 1992; 148 1998; 339 1999; 68 1998; 338 2003; 170 2005; 80 1998; 279 1995; 333 2002; 60 1995; 332 1984; 132 2003; 349 2000; 37 2000; 56 2002; 168 2006; 49 1999; 161 1995; 45 2004; 172 2002; 167 2000; 163 2003; 5 1996; 155 1999; 53 2001; 39 1996; 335 1998; 51 2001; 57 2001; 58 2003; 20 2003; 44 Wright (10.1111/j.1742-1241.2006.01194.x-BIB22|cit22) 2002; 167 Clark (10.1111/j.1742-1241.2006.01194.x-BIB40|cit40) 2004; 89 Beckman (10.1111/j.1742-1241.2006.01194.x-BIB19|cit19) 2005; 80 Lepor (10.1111/j.1742-1241.2006.01194.x-BIB46|cit46) 1998; 51 Rhodes (10.1111/j.1742-1241.2006.01194.x-BIB6|cit6) 1999; 161 Downs (10.1111/j.1742-1241.2006.01194.x-BIB26|cit26) 1998; 279 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB42|cit42) 2004; 63 Anderson (10.1111/j.1742-1241.2006.01194.x-BIB30|cit30) 2001; 39 Shepherd (10.1111/j.1742-1241.2006.01194.x-BIB28|cit28) 1995; 333 Kaplan (10.1111/j.1742-1241.2006.01194.x-BIB44|cit44) 2004; 63 Wasson (10.1111/j.1742-1241.2006.01194.x-BIB35|cit35) 1995; 332 Sacks (10.1111/j.1742-1241.2006.01194.x-BIB27|cit27) 1996; 335 McConnell (10.1111/j.1742-1241.2006.01194.x-BIB33|cit33) 2003; 349 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (10.1111/j.1742-1241.2006.01194.x-BIB29|cit29) 1998; 339 Eastell (10.1111/j.1742-1241.2006.01194.x-BIB31|cit31) 1998; 338 Barry (10.1111/j.1742-1241.2006.01194.x-BIB52|cit52) 1997; 157 Jacobsen (10.1111/j.1742-1241.2006.01194.x-BIB8|cit8) 1996; 155 Boyle (10.1111/j.1742-1241.2006.01194.x-BIB36|cit36) 2004; 45 Jacobsen (10.1111/j.1742-1241.2006.01194.x-BIB13|cit13) 2001; 58 Roberts (10.1111/j.1742-1241.2006.01194.x-BIB7|cit7) 2000; 163 Barkin (10.1111/j.1742-1241.2006.01194.x-BIB51|cit51) 2003; 44 Sarma (10.1111/j.1742-1241.2006.01194.x-BIB9|cit9) 2002; 168 Clark (10.1111/j.1742-1241.2006.01194.x-BIB39|cit39) 1999; 161 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB48|cit48) 2001; 58 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB25|cit25) 2000; 56 Jacobsen (10.1111/j.1742-1241.2006.01194.x-BIB4|cit4) 1997; 158 Flanigan (10.1111/j.1742-1241.2006.01194.x-BIB3|cit3) 1998; 160 Chapple (10.1111/j.1742-1241.2006.01194.x-BIB17|cit17) 2006; 49 McConnell (10.1111/j.1742-1241.2006.01194.x-BIB5|cit5) 1998; 338 Garraway (10.1111/j.1742-1241.2006.01194.x-BIB10|cit10) 1993; 43 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB41|cit41) 2002; 60 Andriole (10.1111/j.1742-1241.2006.01194.x-BIB43|cit43) 2004; 172 AUA Practice Guidelines Committee (10.1111/j.1742-1241.2006.01194.x-BIB11|cit11) 2003; 170 Scientific Committee of the First International Consultation on Incontinence (10.1111/j.1742-1241.2006.01194.x-BIB23|cit23) 2000; 355 Kuritzky (10.1111/j.1742-1241.2006.01194.x-BIB15|cit15) 2003; 5 Ielhé (10.1111/j.1742-1241.2006.01194.x-BIB38|cit38) 1999; 68 Berry (10.1111/j.1742-1241.2006.01194.x-BIB2|cit2) 1984; 132 Barry (10.1111/j.1742-1241.2006.01194.x-BIB20|cit20) 1992; 148 Wei (10.1111/j.1742-1241.2006.01194.x-BIB1|cit1) 2005; 173 Djavan (10.1111/j.1742-1241.2006.01194.x-BIB34|cit34) 2004; 64 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB12|cit12) 1999; 53 Baldwin (10.1111/j.1742-1241.2006.01194.x-BIB50|cit50) 2001; 58 Arrighi (10.1111/j.1742-1241.2006.01194.x-BIB14|cit14) 1991; 38 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB21|cit21) 1999; 53 Stewart (10.1111/j.1742-1241.2006.01194.x-BIB18|cit18) 2003; 20 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB49|cit49) 2006; 97 Lepor (10.1111/j.1742-1241.2006.01194.x-BIB45|cit45) 1995; 45 The Diabetes Control and Complications Trial Research Group (10.1111/j.1742-1241.2006.01194.x-BIB32|cit32) 1993; 329 Bartsch (10.1111/j.1742-1241.2006.01194.x-BIB37|cit37) 2000; 37 Narayan (10.1111/j.1742-1241.2006.01194.x-BIB47|cit47) 1998; 160 Roehrborn (10.1111/j.1742-1241.2006.01194.x-BIB16|cit16) 2000; 163 McNeill (10.1111/j.1742-1241.2006.01194.x-BIB24|cit24) 2001; 57 |
| References_xml | – volume: 51 start-page: 892 year: 1998 end-page: 900 article-title: Phase III multicenter placebo‐controlled study of tamsulosin in benign prostatic hyperplasia publication-title: Urology – volume: 49 start-page: 651 year: 2006 end-page: 59 article-title: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder publication-title: Eur Urol – volume: 43 start-page: 318 year: 1993 end-page: 21 article-title: Impact of previously unrecognized benign prostatic hyperplasia on daily activities of middle‐aged and elderly men publication-title: Br J Gen Pract – volume: 68 start-page: 189 year: 1999 end-page: 95 article-title: Differences in steroid 5 ‐reductase iso‐enzymes expression between normal and pathological human prostate tissue publication-title: J Steroid Biochem Mol Biol – volume: 38 start-page: 4 issue: Suppl. year: 1991 end-page: 8 article-title: Natural history of benign prostatic hyperplasia and risk of prostatectomy publication-title: Urology – volume: 173 start-page: 1256 year: 2005 end-page: 61 article-title: Urologic diseases in America project: benign prostatic hyperplasia publication-title: J Urol – volume: 155 start-page: 595 year: 1996 end-page: 600 article-title: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men publication-title: J Urol – volume: 157 start-page: 10 year: 1997 end-page: 4 article-title: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists publication-title: J Urol – volume: 333 start-page: 1301 year: 1995 end-page: 7 article-title: Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia publication-title: N Engl J Med – volume: 338 start-page: 557 year: 1998 end-page: 63 article-title: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatitic hyperplasia publication-title: N Engl J Med – volume: 339 start-page: 1349 year: 1998 end-page: 57 article-title: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels publication-title: N Engl J Med – volume: 58 start-page: 5 issue: Suppl. 6A year: 2001 end-page: 16 article-title: Natural history of benign prostatic hyperplasia publication-title: Urology – volume: 58 start-page: 203 year: 2001 end-page: 9 article-title: Discontinuation of alpha‐blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia publication-title: Urology – volume: 161 start-page: 268 issue: Suppl. 4 year: 1999 article-title: Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel 5 alpha reductase inhibitor publication-title: J Urol – volume: 172 start-page: 1399 year: 2004 end-page: 403 article-title: Dihydrotestosterone and the prostate: the scientific rationale for 5 ‐reductase inhibitors in the treatment of benign prostatic hyperplasia publication-title: J Urol – volume: 170 start-page: 530 year: 2003 end-page: 47 article-title: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations publication-title: J Urol – volume: 64 start-page: 1144 year: 2004 end-page: 8 article-title: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years publication-title: Urology – volume: 168 start-page: 1446 year: 2002 end-page: 52 article-title: Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men publication-title: J Urol – volume: 45 start-page: 406 year: 1995 end-page: 13 article-title: Long‐term efficacy and safety of terazosin in patients with benign prostatic hyperplasia publication-title: Urology – volume: 161 start-page: 1174 year: 1999 end-page: 9 article-title: Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 70 years old publication-title: J Urol – volume: 5 start-page: S42 issue: Suppl. 5 year: 2003 end-page: S48 article-title: A primary care physician's perspective on benign prostatic hyperplasia publication-title: Rev Urol – volume: 45 start-page: 620 year: 2004 end-page: 7 article-title: 5‐Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH‐related surgery publication-title: Eur Urol – volume: 279 start-page: 1615 year: 1998 end-page: 22 article-title: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels publication-title: JAMA – volume: 329 start-page: 977 year: 1993 end-page: 86 article-title: The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus publication-title: N Engl J Med – volume: 63 start-page: 709 year: 2004 end-page: 15 article-title: Efficacy and safety of dutasteride in the four‐year treatment of men with benign prostatic hyperplasia publication-title: Urology – volume: 56 start-page: 12 issue: Suppl. 5A year: 2000 end-page: 9 article-title: Acute relief or future prevention: is urology ready for preventive health care? publication-title: Urology – volume: 335 start-page: 1001 year: 1996 end-page: 9 article-title: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels publication-title: N Engl J Med – volume: 132 start-page: 474 year: 1984 end-page: 9 article-title: The development of human prostatic hyperplasia with age publication-title: J Urol – volume: 63 start-page: 428 year: 2004 end-page: 34 article-title: Use of alpha‐adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning publication-title: Urology – volume: 160 start-page: 1701 year: 1998 end-page: 6 article-title: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia publication-title: J Urol – volume: 97 start-page: 734 year: 2006 end-page: 41 article-title: Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2‐year placebo‐controlled study publication-title: BJU Int – volume: 148 start-page: 1549 year: 1992 end-page: 57 article-title: The American Urological Association Symptom Index for benign prostatic hyperplasia publication-title: J Urol – volume: 332 start-page: 75 year: 1995 end-page: 9 article-title: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia publication-title: N Engl J Med – volume: 58 start-page: 953 year: 2001 end-page: 9 article-title: Efficacy and safety of once‐daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo‐controlled trial publication-title: Urology – volume: 349 start-page: 2387 year: 2003 end-page: 98 article-title: The long‐term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia publication-title: N Engl J Med – volume: 167 start-page: 2484 year: 2002 end-page: 8 article-title: Prostate specific antigen predicts the long‐term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging publication-title: J Urol – volume: 57 start-page: 459 year: 2001 end-page: 65 article-title: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin publication-title: Urology – volume: 338 start-page: 736 year: 1998 end-page: 46 article-title: Treatment of postmenopausal osteoporosis publication-title: N Engl J Med – volume: 158 start-page: 481 year: 1997 end-page: 7 article-title: Natural history of prostatism: risk factors for acute urinary retention publication-title: J Urol – volume: 39 start-page: 390 year: 2001 end-page: 9 article-title: The progression of benign prostatic hyperplasia: examining the evidence and determining the risk publication-title: Eur Urol – volume: 53 start-page: 473 year: 1999 end-page: 80 article-title: Serum prostate‐specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia publication-title: Urology – volume: 20 start-page: 327 year: 2003 end-page: 36 article-title: Prevalence and burden of overactive bladder in the United States publication-title: World J Urol – volume: 89 start-page: 2179 year: 2004 end-page: 84 article-title: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 ‐reductase inhibitor publication-title: J Clin Endocrinol Metab – volume: 44 start-page: 461 year: 2003 end-page: 6 article-title: Alpha‐blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5 ‐reductase inhibitor dutasteride publication-title: Eur Urol – volume: 163 start-page: 107 year: 2000 end-page: 13 article-title: Longitudinal changes in peak urinary flow rates in a community‐based cohort publication-title: J Urol – volume: 80 start-page: 1356 year: 2005 end-page: 62 article-title: Evaluation and management of benign prostatic hyperplasia publication-title: Mayo Clin Proc – volume: 160 start-page: 12 year: 1998 end-page: 6 article-title: 5‐year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study publication-title: J Urol – volume: 355 start-page: 2153 year: 2000 end-page: 8 article-title: Assessment and treatment of urinary incontinence publication-title: Lancet – volume: 163 start-page: 13 year: 2000 end-page: 20 article-title: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia publication-title: J Urol – volume: 60 start-page: 434 year: 2002 end-page: 41 article-title: Efficacy and safety of a dual inhibitor of 5‐alpha‐reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia publication-title: Urology – volume: 53 start-page: 581 year: 1999 end-page: 9 article-title: Serum prostate‐specific antigen as a predictor or prostate volume in men with benign prostatic hyperplasia publication-title: Urology – volume: 37 start-page: 367 year: 2000 end-page: 80 article-title: Dihydrotestosterone and the concept of 5 ‐reductase inhibition in human benign prostatic hyperplasia publication-title: Eur Urol – volume: 53 start-page: 473 year: 1999 ident: 10.1111/j.1742-1241.2006.01194.x-BIB12|cit12 article-title: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(98)00654-2 contributor: fullname: Roehrborn – volume: 64 start-page: 1144 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB34|cit34 article-title: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years publication-title: Urology doi: 10.1016/j.urology.2004.08.049 contributor: fullname: Djavan – volume: 163 start-page: 13 year: 2000 ident: 10.1111/j.1742-1241.2006.01194.x-BIB16|cit16 article-title: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia publication-title: J Urol doi: 10.1016/S0022-5347(05)67962-1 contributor: fullname: Roehrborn – volume: 63 start-page: 709 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB42|cit42 article-title: Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia publication-title: Urology doi: 10.1016/j.urology.2004.01.001 contributor: fullname: Roehrborn – volume: 161 start-page: 1174 year: 1999 ident: 10.1111/j.1742-1241.2006.01194.x-BIB6|cit6 article-title: Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 70 years old publication-title: J Urol doi: 10.1016/S0022-5347(01)61621-5 contributor: fullname: Rhodes – volume: 349 start-page: 2387 year: 2003 ident: 10.1111/j.1742-1241.2006.01194.x-BIB33|cit33 article-title: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia publication-title: N Engl J Med doi: 10.1056/NEJMoa030656 contributor: fullname: McConnell – volume: 68 start-page: 189 year: 1999 ident: 10.1111/j.1742-1241.2006.01194.x-BIB38|cit38 article-title: Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(99)00030-8 contributor: fullname: Ielhé – volume: 161 start-page: 268 issue: Suppl. 4 year: 1999 ident: 10.1111/j.1742-1241.2006.01194.x-BIB39|cit39 article-title: Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel 5 alpha reductase inhibitor publication-title: J Urol doi: 10.1097/00005392-199904020-00076 contributor: fullname: Clark – volume: 58 start-page: 203 year: 2001 ident: 10.1111/j.1742-1241.2006.01194.x-BIB50|cit50 article-title: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(01)01201-8 contributor: fullname: Baldwin – volume: 168 start-page: 1446 year: 2002 ident: 10.1111/j.1742-1241.2006.01194.x-BIB9|cit9 article-title: Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men publication-title: J Urol doi: 10.1016/S0022-5347(05)64471-0 contributor: fullname: Sarma – volume: 53 start-page: 581 year: 1999 ident: 10.1111/j.1742-1241.2006.01194.x-BIB21|cit21 article-title: Serum prostate-specific antigen as a predictor or prostate volume in men with benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(98)00655-4 contributor: fullname: Roehrborn – volume: 51 start-page: 892 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB46|cit46 article-title: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(98)00126-5 contributor: fullname: Lepor – volume: 355 start-page: 2153 year: 2000 ident: 10.1111/j.1742-1241.2006.01194.x-BIB23|cit23 article-title: Assessment and treatment of urinary incontinence publication-title: Lancet doi: 10.1016/S0140-6736(00)02389-8 contributor: fullname: Scientific Committee of the First International Consultation on Incontinence – volume: 163 start-page: 107 year: 2000 ident: 10.1111/j.1742-1241.2006.01194.x-BIB7|cit7 article-title: Longitudinal changes in peak urinary flow rates in a community-based cohort publication-title: J Urol doi: 10.1016/S0022-5347(05)67984-0 contributor: fullname: Roberts – volume: 335 start-page: 1001 year: 1996 ident: 10.1111/j.1742-1241.2006.01194.x-BIB27|cit27 article-title: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels publication-title: N Engl J Med doi: 10.1056/NEJM199610033351401 contributor: fullname: Sacks – volume: 49 start-page: 651 year: 2006 ident: 10.1111/j.1742-1241.2006.01194.x-BIB17|cit17 article-title: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder publication-title: Eur Urol doi: 10.1016/j.eururo.2006.02.018 contributor: fullname: Chapple – volume: 60 start-page: 434 year: 2002 ident: 10.1111/j.1742-1241.2006.01194.x-BIB41|cit41 article-title: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(02)01905-2 contributor: fullname: Roehrborn – volume: 160 start-page: 1701 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB47|cit47 article-title: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia publication-title: J Urol doi: 10.1016/S0022-5347(01)62386-3 contributor: fullname: Narayan – volume: 167 start-page: 2484 year: 2002 ident: 10.1111/j.1742-1241.2006.01194.x-BIB22|cit22 article-title: Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging publication-title: J Urol doi: 10.1016/S0022-5347(05)65010-0 contributor: fullname: Wright – volume: 339 start-page: 1349 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB29|cit29 article-title: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels publication-title: N Engl J Med doi: 10.1056/NEJM199811053391902 contributor: fullname: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group – volume: 173 start-page: 1256 year: 2005 ident: 10.1111/j.1742-1241.2006.01194.x-BIB1|cit1 article-title: Urologic diseases in America project: benign prostatic hyperplasia publication-title: J Urol doi: 10.1097/01.ju.0000155709.37840.fe contributor: fullname: Wei – volume: 58 start-page: 953 year: 2001 ident: 10.1111/j.1742-1241.2006.01194.x-BIB48|cit48 article-title: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial publication-title: Urology doi: 10.1016/S0090-4295(01)01448-0 contributor: fullname: Roehrborn – volume: 89 start-page: 2179 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB40|cit40 article-title: Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2003-030330 contributor: fullname: Clark – volume: 58 start-page: 5 issue: Suppl. 6A year: 2001 ident: 10.1111/j.1742-1241.2006.01194.x-BIB13|cit13 article-title: Natural history of benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(01)01298-5 contributor: fullname: Jacobsen – volume: 279 start-page: 1615 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB26|cit26 article-title: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels publication-title: JAMA doi: 10.1001/jama.279.20.1615 contributor: fullname: Downs – volume: 132 start-page: 474 year: 1984 ident: 10.1111/j.1742-1241.2006.01194.x-BIB2|cit2 article-title: The development of human prostatic hyperplasia with age publication-title: J Urol doi: 10.1016/S0022-5347(17)49698-4 contributor: fullname: Berry – volume: 338 start-page: 736 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB31|cit31 article-title: Treatment of postmenopausal osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJM199803123381107 contributor: fullname: Eastell – volume: 172 start-page: 1399 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB43|cit43 article-title: Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia publication-title: J Urol doi: 10.1097/01.ju.0000139539.94828.29 contributor: fullname: Andriole – volume: 155 start-page: 595 year: 1996 ident: 10.1111/j.1742-1241.2006.01194.x-BIB8|cit8 article-title: Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men publication-title: J Urol doi: 10.1016/S0022-5347(01)66461-9 contributor: fullname: Jacobsen – volume: 5 start-page: S42 issue: Suppl. 5 year: 2003 ident: 10.1111/j.1742-1241.2006.01194.x-BIB15|cit15 article-title: A primary care physician's perspective on benign prostatic hyperplasia publication-title: Rev Urol contributor: fullname: Kuritzky – volume: 160 start-page: 12 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB3|cit3 article-title: 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study publication-title: J Urol doi: 10.1016/S0022-5347(01)63011-8 contributor: fullname: Flanigan – volume: 39 start-page: 390 year: 2001 ident: 10.1111/j.1742-1241.2006.01194.x-BIB30|cit30 article-title: The progression of benign prostatic hyperplasia: examining the evidence and determining the risk publication-title: Eur Urol doi: 10.1159/000052475 contributor: fullname: Anderson – volume: 338 start-page: 557 year: 1998 ident: 10.1111/j.1742-1241.2006.01194.x-BIB5|cit5 article-title: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatitic hyperplasia publication-title: N Engl J Med doi: 10.1056/NEJM199802263380901 contributor: fullname: McConnell – volume: 20 start-page: 327 year: 2003 ident: 10.1111/j.1742-1241.2006.01194.x-BIB18|cit18 article-title: Prevalence and burden of overactive bladder in the United States publication-title: World J Urol doi: 10.1007/s00345-002-0301-4 contributor: fullname: Stewart – volume: 170 start-page: 530 year: 2003 ident: 10.1111/j.1742-1241.2006.01194.x-BIB11|cit11 article-title: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations publication-title: J Urol doi: 10.1097/01.ju.0000078083.38675.79 contributor: fullname: AUA Practice Guidelines Committee – volume: 148 start-page: 1549 year: 1992 ident: 10.1111/j.1742-1241.2006.01194.x-BIB20|cit20 article-title: The American Urological Association Symptom Index for benign prostatic hyperplasia publication-title: J Urol doi: 10.1016/S0022-5347(17)36966-5 contributor: fullname: Barry – volume: 158 start-page: 481 year: 1997 ident: 10.1111/j.1742-1241.2006.01194.x-BIB4|cit4 article-title: Natural history of prostatism: risk factors for acute urinary retention publication-title: J Urol doi: 10.1016/S0022-5347(01)64508-7 contributor: fullname: Jacobsen – volume: 38 start-page: 4 issue: Suppl. year: 1991 ident: 10.1111/j.1742-1241.2006.01194.x-BIB14|cit14 article-title: Natural history of benign prostatic hyperplasia and risk of prostatectomy publication-title: Urology doi: 10.1016/0090-4295(91)80191-9 contributor: fullname: Arrighi – volume: 37 start-page: 367 year: 2000 ident: 10.1111/j.1742-1241.2006.01194.x-BIB37|cit37 article-title: Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia publication-title: Eur Urol doi: 10.1159/000020181 contributor: fullname: Bartsch – volume: 97 start-page: 734 year: 2006 ident: 10.1111/j.1742-1241.2006.01194.x-BIB49|cit49 article-title: Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study publication-title: BJU Int doi: 10.1111/j.1464-410X.2006.06110.x contributor: fullname: Roehrborn – volume: 332 start-page: 75 year: 1995 ident: 10.1111/j.1742-1241.2006.01194.x-BIB35|cit35 article-title: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia publication-title: N Engl J Med doi: 10.1056/NEJM199501123320202 contributor: fullname: Wasson – volume: 63 start-page: 428 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB44|cit44 article-title: Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning publication-title: Urology doi: 10.1016/j.urology.2003.09.063 contributor: fullname: Kaplan – volume: 333 start-page: 1301 year: 1995 ident: 10.1111/j.1742-1241.2006.01194.x-BIB28|cit28 article-title: Prevention of coronary heart disease with pravastatin in men with hypercholestrolemia publication-title: N Engl J Med doi: 10.1056/NEJM199511163332001 contributor: fullname: Shepherd – volume: 157 start-page: 10 year: 1997 ident: 10.1111/j.1742-1241.2006.01194.x-BIB52|cit52 article-title: The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists publication-title: J Urol doi: 10.1016/S0022-5347(01)65267-4 contributor: fullname: Barry – volume: 329 start-page: 977 year: 1993 ident: 10.1111/j.1742-1241.2006.01194.x-BIB32|cit32 article-title: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus publication-title: N Engl J Med doi: 10.1056/NEJM199309303291401 contributor: fullname: The Diabetes Control and Complications Trial Research Group – volume: 80 start-page: 1356 year: 2005 ident: 10.1111/j.1742-1241.2006.01194.x-BIB19|cit19 article-title: Evaluation and management of benign prostatic hyperplasia publication-title: Mayo Clin Proc doi: 10.4065/80.10.1356 contributor: fullname: Beckman – volume: 45 start-page: 406 year: 1995 ident: 10.1111/j.1742-1241.2006.01194.x-BIB45|cit45 article-title: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia publication-title: Urology doi: 10.1016/S0090-4295(99)80008-9 contributor: fullname: Lepor – volume: 57 start-page: 459 year: 2001 ident: 10.1111/j.1742-1241.2006.01194.x-BIB24|cit24 article-title: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin publication-title: Urology doi: 10.1016/S0090-4295(00)01021-9 contributor: fullname: McNeill – volume: 43 start-page: 318 year: 1993 ident: 10.1111/j.1742-1241.2006.01194.x-BIB10|cit10 article-title: Impact of previously unrecognized benign prostatic hyperplasia on daily activities of middle-aged and elderly men publication-title: Br J Gen Pract contributor: fullname: Garraway – volume: 56 start-page: 12 issue: Suppl. 5A year: 2000 ident: 10.1111/j.1742-1241.2006.01194.x-BIB25|cit25 article-title: Acute relief or future prevention: is urology ready for preventive health care? publication-title: Urology doi: 10.1016/S0090-4295(00)00743-3 contributor: fullname: Roehrborn – volume: 45 start-page: 620 year: 2004 ident: 10.1111/j.1742-1241.2006.01194.x-BIB36|cit36 article-title: 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery publication-title: Eur Urol doi: 10.1016/j.eururo.2003.09.012 contributor: fullname: Boyle – volume: 44 start-page: 461 year: 2003 ident: 10.1111/j.1742-1241.2006.01194.x-BIB51|cit51 article-title: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5α-reductase inhibitor dutasteride publication-title: Eur Urol doi: 10.1016/S0302-2838(03)00367-1 contributor: fullname: Barkin |
| SSID | ssj0025580 |
| Score | 1.846407 |
| SecondaryResourceType | review_article |
| Snippet | Summary
Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has... Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for... |
| SourceID | proquest crossref pubmed pascalfrancis wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1609 |
| SubjectTerms | Adrenergic alpha-Antagonists - therapeutic use Aged Algorithms Benign prostatic hyperplasia Biological and medical sciences Cholestenone 5 alpha-Reductase - antagonists & inhibitors diagnosis Disease Progression enlarged prostate Enzyme Inhibitors - therapeutic use Family Practice - methods General aspects Humans lower urinary tract symptoms Male Medical sciences Middle Aged Nephrology. Urinary tract diseases primary care Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - therapy Referral and Consultation Risk Factors treatment Tumors of the urinary system Urinary tract. Prostate gland Urologic Diseases - etiology Urologic Diseases - therapy |
| Title | Managing enlarged prostate in primary care |
| URI | https://api.istex.fr/ark:/67375/WNG-NCRKSBKD-D/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1742-1241.2006.01194.x https://www.ncbi.nlm.nih.gov/pubmed/17109668 https://search.proquest.com/docview/68164661 |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB6hVkJceD8MpfiAOCA58tr78rFNKKVVI1So6G21TwkFuahJpIpfz4ztpKTqASFuexl7PbOz8633mxmAt2VA0G2FLrxWseAYQwvrnCiED8zW2pWuK5l_MpWHZ_zoXJwP_CfKhenrQ6x_uJFndPs1Obh1800nx2NdgfGJDXcKDA_kI8KTrFbE7pqcritJIXDWfcIwJRrhQr5J6rnlQRuRapuUfkXMSTtH5aW-68VtsHQT5XZh6uABzFYf2LNTZqPlwo38rxu1H_-PBh7C_QHN5nv98nsEd2L7GO6eDPf1T-D9qg1SHtsfxDkP-U9KM0GAm39vcdyVusiJfvYUzg4-fB0fFkN3hsJzLTm6l2RSNkn6qq554yPjsXK-rjDmpTLyhqdQpZBErZrKqRRUk4S2KBuYE7yun8FWe9HGF5CX1vnoEKvqELhHiGRLpaiwfrRRJJEyYCtLmGFm5o_DCyrBkBKopaY0nRLMVQbvOpOtBezljEhsSphv049mOj49_rJ_PDGTDHY3bHr9Bo17G04kgzcrIxv0PbpQsW28WM6N1FSdTbIMnve2v5YliquUOgPVWfCvp20-HY0_0_DlP0u-gnvV0F2pZDuwtbhcxteInBZut_OJ327HBiQ |
| link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hVgIuvB8p0OaAOCBlFSe24xxhl7LtdleotKI3y08JtUqrdleq-PXMJNktW_WAEDdfJnFmPJ7P8TczAO9zj6DbCJU5VYWMYwzNjLUiE84zUyqb27Zk_nQmx8d8_0Sc9O2AKBemqw-x-uFGntHu1-Tg9EN63cvxXJdhgGL9pQLDE_kAAeUmen9JfRxGh6taUgidVZcyTKlGuJRv03rueNJarNoktV8Td9Jcofpi1_fiLmC6jnPbQLX7GM6Wn9jxU04Hi7kduF-3qj_-Jx08gUc9oE0_dSvwKdwLzTO4P-2v7J_Dx2UnpDQ0Z0Q79-kFZZogxk1_Njhuq12kxEB7Ace7X46G46xv0JA5riRHD5NMyjpKV5Qlr11gPBTWlQWGvZgHXvPoi-ijKKu6sFX0VR2FMijrmRW8LF_CRnPehNeQ5sa6YBGuKu-5Q5Rk8qqi2vrBBBFFTIAtTaH7mek_zi-oBE1KoK6aUrdK0NcJfGhtthIwl6fEY6uE_jH7qmfDw8n3z5ORHiWwvWbUmzco3N5wIgnsLK2s0f3oTsU04XxxpaWiAm2SJfCqM_6NLLFcpVQJVK0J_3raem9_-I2GW_8suQMPxkfTA32wN5u8gYdF32wpZ29hY365CO8QSM3tdusgvwHeOQo8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hVqq48IaGQpsD4oCUVZzYjnOEXZa2S1dVoaI3y08JLUqrdleq-uuZSbJbtuoBIW6-TOLMeDyf429mAN7lHkG3ESpzqgoZxxiaGWtFJpxnplQ2t23J_KOp3D_lh2firOc_US5MVx9i9cONPKPdr8nBL3xcd3I81mUYn1h_p8DwQD5APLnJJQJhAkgnq1JSiJxVlzFMmUa4ku-yeu550lqo2iStXxN10lyh9mLX9uI-XLoOc9s4NX4Ms-UXdvSU2WAxtwN3c6f44_9RwRN41MPZ9GO3_p7Cg9A8g62j_sL-OXxY9kFKQ_OLSOc-vaA8E0S46c8Gx22ti5T4Zy_gdPz5-3A_69szZI4rydG_JJOyjtIVZclrFxgPhXVlgUEv5oHXPPoi-ijKqi5sFX1VR6EMynpmBS_Ll7DRnDdhG9LcWBcsglXlPXeIkUxeVVRZP5ggoogJsKUldD8z_cfpBZWgSQnUU1PqVgn6OoH3rclWAuZyRiy2Sugf0y96OjyZfPs0GelRArtrNr19g8LNDSeSwN7SyBqdj25UTBPOF1daKirPJlkCrzrb38oSx1VKlUDVWvCvp60PDofHNHz9z5J7sHU8GuuvB9PJDjws-k5LOXsDG_PLRXiLKGpud1v3-A2glwjr |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Managing+enlarged+prostate+in+primary+care&rft.jtitle=International+journal+of+clinical+practice+%28Esher%29&rft.au=NASLUND%2C+M.+J.&rft.au=COSTA%2C+F.+J.&rft.au=MINER%2C+M.+M.&rft.date=2006-12-01&rft.issn=1368-5031&rft.volume=60&rft.issue=12&rft.spage=1609&rft.epage=1615&rft_id=info:doi/10.1111%2Fj.1742-1241.2006.01194.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1742_1241_2006_01194_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1368-5031&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1368-5031&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1368-5031&client=summon |